Moreover, atorvastatin combined with ROR α/γ agonists was found to have a synergistic effect in inhibiting the proliferation and migration of CRC cells, which provides a new strategy for CRC therapy by inhibiting the cholesterol-ROR α/γ–c-myc axis [91]. This evidence concerns the gene LINC-ROR and colorectal carcinoma.